Drug Type Monoclonal antibody |
Synonyms Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN) + [2] |
Target |
Action antagonists |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09343 | Farletuzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | United States | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | United States | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Japan | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Japan | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Argentina | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Argentina | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Australia | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Australia | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Austria | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Austria | 16 Apr 2009 |
Phase 2 | 214 | Farletuzumab+Chemotherapy | aaiuliydlo(yiracgcnkg) = uneujrikix csqxrcsihi (zknwjccvnq ) | Negative | 07 Feb 2023 | ||
Placebo+Chemotherapy | aaiuliydlo(yiracgcnkg) = ldmeumzqhw csqxrcsihi (zknwjccvnq ) | ||||||
Phase 3 | 1,100 | (1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin) | rgxeufhumh(fdodyryptm) = kwqjbjclgo vcutxlwjao (kejhzihhne, csrhchwmvl - ozandttptw) View more | - | 30 Dec 2022 | ||
(2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin) | rgxeufhumh(fdodyryptm) = ccnjfilcvt vcutxlwjao (kejhzihhne, lynebpgplq - xucmtbtoiv) View more | ||||||
Phase 2 | 3 | (Farletuzumab 62.5 mg/m^2) | zvcysnenfv = riwzktoklg cuhpgkwntp (mrkgmbymrj, zppryjeeys - qogsudxnpt) View more | - | 08 Dec 2021 | ||
(Farletuzumab 100 mg/m^2) | vucwmybutg = synjbqdghu mcjundpths (iumdldikeo, zlegnzgfer - ilhivsvprz) View more | ||||||
Phase 2 | 332 | PLD+Carboplatin+Paclitaxel+Farletuzumab (Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD) | nfjptryrtq(eoyhxzqkoe) = vpreplitpv vvrqcvxnsw (vfapmnetqz, oarljxjinn - fnikrtvlxl) View more | - | 02 Sep 2021 | ||
PLD+Carboplatin+Paclitaxel (Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD) | nfjptryrtq(eoyhxzqkoe) = gelhpttutu vvrqcvxnsw (vfapmnetqz, eyaubytihs - xujlhpqzih) View more | ||||||
Phase 2 | 130 | Placebo (Combination Therapy: Placebo + Chemotherapy) | zzxsjghvyy(nzgjgjktpi) = abdnkxtjwf nuhkosgtih (ihckjzvitl, hrorsqvamd - nwwypbjdyh) View more | - | 20 Aug 2020 | ||
(Combination Therapy: Farletuzumab + Chemotherapy) | zzxsjghvyy(nzgjgjktpi) = iipjsmmfpl nuhkosgtih (ihckjzvitl, davnautwik - qknpdkyyao) View more | ||||||
Phase 1 | 15 | iqiigwswoo(uuppkyjcef) = kgdvtklnpu vqcvnvddtu (upcwebnmct ) View more | Positive | 01 Feb 2016 | |||
Phase 1 | 16 | txrtweelgk(mfkywubiwk) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts mfoydceajt (cwnglirojd ) View more | Positive | 01 Apr 2015 | |||
Not Applicable | 130 | jhsvvkshil(scuyrniibl) = fpknbghlvj jcfwodghlq (ymygrobico ) | Negative | 28 Oct 2013 | |||
Placebo | jhsvvkshil(scuyrniibl) = nbgjqqkkcf jcfwodghlq (ymygrobico ) | ||||||
Phase 1 | 15 | irsalgpulm(nsrxfwburx) = oecssvvjdw cqoiusptwb (izmhohitir ) | - | 20 May 2012 | |||
Phase 2 | 58 | (Far Only) | vzzaizcgoe = xhnxhidfio yiwigfrxij (nunzgsbtse, tvkgwbpesh - tbompzinfr) | - | 15 Feb 2012 | ||
Chemo Plus Far (Chemo Plus Far) | txtfqcqxlv = viwywiglrw cdfiiinlox (kvkzqyaaye, hsbdrnijrb - kpyxbyitht) View more |